0001516551-24-000008.txt : 20240212 0001516551-24-000008.hdr.sgml : 20240212 20240212161820 ACCESSION NUMBER: 0001516551-24-000008 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 15 CONFORMED PERIOD OF REPORT: 20240212 ITEM INFORMATION: Other Events ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20240212 DATE AS OF CHANGE: 20240212 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Skye Bioscience, Inc. CENTRAL INDEX KEY: 0001516551 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 450692882 STATE OF INCORPORATION: NV FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 000-55136 FILM NUMBER: 24620188 BUSINESS ADDRESS: STREET 1: 11250 EL CAMINO REAL, SUITE 100 CITY: SAN DIEGO STATE: CA ZIP: 92130 BUSINESS PHONE: (858) 410-0266 MAIL ADDRESS: STREET 1: 11250 EL CAMINO REAL, SUITE 100 CITY: SAN DIEGO STATE: CA ZIP: 92130 FORMER COMPANY: FORMER CONFORMED NAME: Emerald Bioscience, Inc. DATE OF NAME CHANGE: 20190325 FORMER COMPANY: FORMER CONFORMED NAME: Nemus Bioscience, Inc. DATE OF NAME CHANGE: 20141030 FORMER COMPANY: FORMER CONFORMED NAME: LOAD GUARD LOGISTICS, INC. DATE OF NAME CHANGE: 20121107 8-K 1 skye-20240212.htm 8-K skye-20240212
FALSE000151655100015165512024-02-122024-02-12

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
 
FORM 8-K
 
CURRENT REPORT
 
Pursuant to Section 13 or 15(d) of
the Securities Exchange Act of 1934
 
Date of report (Date of earliest event reported): February 12, 2024
 
SKYE BIOSCIENCE, INC.
(Exact name of registrant as specified in its charter)

Nevada 000-55136 45-0692882
(State or other jurisdiction of incorporation) (Commission File Number) (I.R.S. Employer Identification Number)
 
11250 El Camino Real, Suite 100, San Diego, CA 92130
(Address of principal executive offices)
 
(858) 410-0266
(Registrant’s telephone number, including area code)
_________________________
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligations of the registrant under any of the following provisions.
☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each class
Trading
Symbol(s)
Name of each exchange
on which registered
N/A
N/A
N/A


Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐


Item 8.01 Other Events.
The following unaudited pro forma balance sheet has been prepared to illustrate the impact of a number of events that followed the close of the Company’s third quarter ended September 30, 2023, including (i) the Company’s receipt of proceeds from the private placement of the Company’s common stock on January 31, 2024, (ii) the sale of real-estate on January 19, 2024 and (iii) the increase to the company's authorized shares of capital stock, and the Company’s resulting compliance with the minimum $5 million stockholders’ equity requirement for initial listing on The Nasdaq Capital Market. In that regard, the Company believes that as of the date of this Form 8-K filing, stockholders’ equity exceeds $5 million.

The unaudited pro forma balance sheet is based on the Company’s unaudited balance sheet as of September 30, 2023, as contained in the Company's 10-Q for the quarter then ended, filed with the Securities and Exchange Commission on November 14, 2023, adjusted to reflect the subsequent events after the balance sheet date of September 30, 2023, through the date of filing, as set out in Note 13 of the 10-Q and as described above, as if the events occurred on September 30, 2023.
This unaudited pro forma balance sheet is for informational purposes only, and should be read in conjunction with the more detailed unaudited condensed consolidated financial statements and related notes thereto included in the Company’s Form 10-Q for the quarter ended September 30, 2023.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits
Exhibit No.Description
99.1
104Cover Page Interactive Data File (embedded within the inline XBRL document)



SIGNATURES
 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
 
 
                        SKYE BIOSCIENCE, INC.
  
  
Dated: February 12, 2024
/s/  Kaitlyn Arsenault
 Name: Kaitlyn Arsenault
 Title: Chief Financial Officer

 EX-99.1 2 a991_unauditedproformabala.htm EX-99.1 Document
Exhibit 99.1
SKYE BIOSCIENCE, INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED BALANCE SHEETS
(Unaudited)

September 30,
2023		Pro Forma AdjustmentsAs Adjusted
September 30,
2023
ASSETS
Current assets
Cash and cash equivalents$5,126,245 $47,356,211 (1)(2)$52,482,456 
Restricted cash9,084,799 9,084,799 
Prepaid expenses207,226 207,226 
Other current assets867,919 867,919 
Total current assets15,286,189 47,356,211 62,642,400 
Property and equipment, net55,280 55,280 
Operating lease right-of-use asset254,552 254,552 
Other assets8,309 8,309 
Total assets$15,604,330 $47,356,211 $62,960,541 
LIABILITIES AND STOCKHOLDERS’ EQUITY
Current liabilities
Accounts payable$1,631,451 $1,631,451 
Accounts payable - related parties11,300 11,300 
Accrued interest - related party60,274 60,274 
Accrued payroll liabilities645,830 645,830 
Insurance premium loan payable22,654 22,654 
Other current liabilities921,549 921,549 
Estimate for legal contingency6,212,319 6,212,319 
Convertible note - related party, net of discount4,144,508 4,144,508 
Operating lease liability, current portion68,677 68,677 
Total current liabilities13,718,562 — 13,718,562 
Non-current liabilities
Operating lease liability, net of current portion190,510 190,510 
Total liabilities13,909,072 — 13,909,072 
Commitments and contingencies (Note 12)


Stockholders’ equity
Preferred stock, $0.001 par value; 200,000 shares authorized at September 30, 2023; no shares issued and outstanding at September 30, 2023— — 
Common stock, $0.001 par value; 100,000,000 shares authorized at September 30, 2023; 24,052,574 shares issued and outstanding at September 30, 202312,338 11,714 (1)(3)24,052 
Additional paid-in-capital101,645,539 46,204,925 (1)147,850,464 
Accumulated deficit(99,962,619)1,139,572 (2)(98,823,047)
Total stockholders’ equity1,695,258 47,356,211 49,051,469 
Total liabilities and stockholders’ equity $15,604,330 $47,356,211 $62,960,541 

    
Notes to the Pro Forma Balance Sheet:

This Pro Forma Balance Sheet reflects the Skye Bioscience, Inc. (SKYE) Balance Sheet as reported in the Company's 10-Q for the quarter ended September 30, 2023, filed with the Securities and Exchange Commission on November 14, 2023, adjusted to reflect the subsequent events after the balance sheet date of September 30, 2023 through the date of filing, as set out in Note 13 of the 10-Q as described below:

(1)The sale of 11,713,664 shares of Common Stock and 9,978,739 pre-funded warrants under the Securities Purchase Agreement dated January 29, 2024 providing total gross proceeds of $50 million and net proceeds of approximately $46.2 million net of placement agent fees and offering costs.
(2)To record the gain from the sale of real estate held by Avalite Sciences, Inc.
(3)To reflect the increase in authorized shares, effective November 6, 2023.















 EX-101.SCH 3 skye-20240212.xsd XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 0000001 - Document - Cover Page link:presentationLink link:calculationLink link:definitionLink EX-101.LAB 4 skye-20240212_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT Entity Central Index Key Entity Central Index Key Entity Address, Address Line Two Entity Address, Address Line Two Entity Tax Identification Number Entity Tax Identification Number Entity Address, Address Line One Entity Address, Address Line One Entity File Number Entity File Number Pre-commencement Issuer Tender Offer Pre-commencement Issuer Tender Offer Soliciting Material Soliciting Material Entity Address, City or Town Entity Address, City or Town Entity Incorporation, State or Country Code Entity Incorporation, State or Country Code Local Phone Number Local Phone Number Entity Address, Postal Zip Code Entity Address, Postal Zip Code Written Communications Written Communications City Area Code City Area Code Cover [Abstract] Document Type Document Type Amendment Flag Amendment Flag Entity Registrant Name Entity Registrant Name Entity Emerging Growth Company Entity Emerging Growth Company Entity Address, State or Province Entity Address, State or Province Document Period End Date Document Period End Date Pre-commencement Tender Offer Pre-commencement Tender Offer EX-101.PRE 5 skye-20240212_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT XML 6 R1.htm IDEA: XBRL DOCUMENT v3.24.0.1
Cover Page
Feb. 12, 2024
Cover [Abstract]  
Document Type 8-K
Document Period End Date Feb. 12, 2024
Entity Registrant Name SKYE BIOSCIENCE, INC.
Entity Incorporation, State or Country Code NV
Entity File Number 000-55136
Entity Tax Identification Number 45-0692882
Entity Address, Address Line One 11250 El Camino Real
Entity Address, Address Line Two Suite 100
Entity Address, City or Town San Diego
Entity Address, State or Province CA
Entity Address, Postal Zip Code 92130
City Area Code 858
Local Phone Number 410-0266
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Entity Emerging Growth Company false
Amendment Flag false
Entity Central Index Key 0001516551
EXCEL 8 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 9 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 10 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 12 FilingSummary.xml IDEA: XBRL DOCUMENT 3.24.0.1 html 1 20 1 false 0 0 false 0 false false R1.htm 0000001 - Document - Cover Page Sheet http://skyebioscience.com/role/CoverPage Cover Page Cover 1 false false All Reports Book All Reports skye-20240212.htm skye-20240212.xsd skye-20240212_lab.xml skye-20240212_pre.xml http://xbrl.sec.gov/dei/2022 true false JSON 14 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "skye-20240212.htm": { "nsprefix": "skye", "nsuri": "http://skyebioscience.com/20240212", "dts": { "inline": { "local": [ "skye-20240212.htm" ] }, "schema": { "local": [ "skye-20240212.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.sec.gov/dei/2022/dei-2022.xsd" ] }, "labelLink": { "local": [ "skye-20240212_lab.xml" ] }, "presentationLink": { "local": [ "skye-20240212_pre.xml" ] } }, "keyStandard": 20, "keyCustom": 0, "axisStandard": 0, "axisCustom": 0, "memberStandard": 0, "memberCustom": 0, "hidden": { "total": 2, "http://xbrl.sec.gov/dei/2022": 2 }, "contextCount": 1, "entityCount": 1, "segmentCount": 0, "elementCount": 21, "unitCount": 0, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2022": 20 }, "report": { "R1": { "role": "http://skyebioscience.com/role/CoverPage", "longName": "0000001 - Document - Cover Page", "shortName": "Cover Page", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "c-1", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "skye-20240212.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "skye-20240212.htm", "first": true, "unique": true } } }, "tag": { "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "AmendmentFlag", "presentation": [ "http://skyebioscience.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Amendment Flag", "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "CityAreaCode", "presentation": [ "http://skyebioscience.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "City Area Code", "label": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "label": "Cover [Abstract]", "documentation": "Cover page." } } }, "auth_ref": [] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "DocumentPeriodEndDate", "presentation": [ "http://skyebioscience.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Document Period End Date", "label": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "DocumentType", "presentation": [ "http://skyebioscience.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Document Type", "label": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "EntityAddressAddressLine1", "presentation": [ "http://skyebioscience.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, Address Line One", "label": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine2": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "EntityAddressAddressLine2", "presentation": [ "http://skyebioscience.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, Address Line Two", "label": "Entity Address, Address Line Two", "documentation": "Address Line 2 such as Street or Suite number" } } }, "auth_ref": [] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "EntityAddressCityOrTown", "presentation": [ "http://skyebioscience.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, City or Town", "label": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://skyebioscience.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, Postal Zip Code", "label": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "EntityAddressStateOrProvince", "presentation": [ "http://skyebioscience.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, State or Province", "label": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "EntityCentralIndexKey", "presentation": [ "http://skyebioscience.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Central Index Key", "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r0" ] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://skyebioscience.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Emerging Growth Company", "label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r0" ] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "EntityFileNumber", "presentation": [ "http://skyebioscience.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity File Number", "label": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://skyebioscience.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Incorporation, State or Country Code", "label": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "EntityRegistrantName", "presentation": [ "http://skyebioscience.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Registrant Name", "label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r0" ] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "EntityTaxIdentificationNumber", "presentation": [ "http://skyebioscience.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Tax Identification Number", "label": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r0" ] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "LocalPhoneNumber", "presentation": [ "http://skyebioscience.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Local Phone Number", "label": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "dei_PreCommencementIssuerTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "PreCommencementIssuerTenderOffer", "presentation": [ "http://skyebioscience.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Pre-commencement Issuer Tender Offer", "label": "Pre-commencement Issuer Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act." } } }, "auth_ref": [ "r1" ] }, "dei_PreCommencementTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "PreCommencementTenderOffer", "presentation": [ "http://skyebioscience.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Pre-commencement Tender Offer", "label": "Pre-commencement Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act." } } }, "auth_ref": [ "r2" ] }, "dei_SolicitingMaterial": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "SolicitingMaterial", "presentation": [ "http://skyebioscience.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Soliciting Material", "label": "Soliciting Material", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act." } } }, "auth_ref": [ "r3" ] }, "dei_WrittenCommunications": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "WrittenCommunications", "presentation": [ "http://skyebioscience.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Written Communications", "label": "Written Communications", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act." } } }, "auth_ref": [ "r4" ] } } } }, "std_ref": { "r0": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r1": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "13e", "Subsection": "4c" }, "r2": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "14d", "Subsection": "2b" }, "r3": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Section": "14a", "Number": "240", "Subsection": "12" }, "r4": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "425" } } } ZIP 15 0001516551-24-000008-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001516551-24-000008-xbrl.zip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end XML 16 skye-20240212_htm.xml IDEA: XBRL DOCUMENT 0001516551 2024-02-12 2024-02-12 false 0001516551 8-K 2024-02-12 SKYE BIOSCIENCE, INC. NV 000-55136 45-0692882 11250 El Camino Real Suite 100 San Diego CA 92130 858 410-0266 false false false false false